Health Canada authorizes SPIKEVAX COVID-19 Vaccine in Children (6-11 Years).-Moderna Inc.
Moderna, Inc. has announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX, in a two-dose series of 50 µg per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 to 11 years.
The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union.
Moderna's vaccine was investigated in the ongoing Phase II/III "KidCOVE" study, a randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of SPIKEVAX (mRNA-1273) given to healthy children 28 days apart. Data submitted to Health Canada from over 4,000 children demonstrated that vaccination of children aged 6 to 11 years with a 50 ?g mRNA-1273 primary series is associated with non-inferior anti-SARS-CoV-2 neutralizing antibody responses when compared to that in individuals 18 to 25 years old from the Phase III COVE study. Positive direct efficacy of two 50 ug doses of mRNA-1273 was also demonstrated, and vaccination was generally well tolerated..
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins